Lexicon Pharma (LXRX) Announces Sotagliflozin Phase 3 in T1D Met Primary Endpoint
Tweet Send to a Friend
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that the pivotal inTandem1 Phase 3 clinical trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
